Zobrazeno 1 - 10
of 198
pro vyhledávání: '"D, Perner"'
Autor:
A. A. P. Pszenny, J. Moldanová, W. C. Keene, R. Sander, J. R. Maben, M. Martinez, P. J. Crutzen, D. Perner, R. G. Prinn
Publikováno v:
Atmospheric Chemistry and Physics, Vol 4, Iss 1, Pp 147-168 (2004)
Halogen species (HCl* (primarily HCl), Cl* (including Cl2 and HOCl), BrO, total gaseous inorganic Br and size-resolved particulate Cl- and Br -) and related chemical and physical parameters were measured in surface air at Oahu, Hawaii during Septembe
Externí odkaz:
https://doaj.org/article/f21c714d38294472a31a2f899a7aa440
Autor:
M. Vrekoussis, M. Kanakidou, N. Mihalopoulos, P. J. Crutzen, J. Lelieveld, D. Perner, H. Berresheim, E. Baboukas
Publikováno v:
Atmospheric Chemistry and Physics, Vol 4, Iss 1, Pp 169-182 (2004)
During the MINOS campaign (28 July-18 August 2001) the nitrate (NO3) radical was measured at Finokalia station, on the north coast of Crete in South-East Europe using a long path (10.4 km) Differential Optical Absorption Spectroscopy instrument (DOAS
Externí odkaz:
https://doaj.org/article/2b31558ab25b44c5830b6c11b88cee24
Publikováno v:
Atmospheric Chemistry and Physics, Vol 3, Iss 6, Pp 1965-1979 (2003)
A new 4p-spectroradiometer was developed for measuring actinic flux especially under cloudy conditions based on a fixed grating imaging spectrograph and a CCD-detector leading to a simultaneous measurement of the spectrum. The new instrument incorpor
Externí odkaz:
https://doaj.org/article/6c2749f19bd345b3ab00513dcacfa354
Publikováno v:
Annales Geophysicae, Vol 17, Pp 941-956 (1999)
During the Arctic Tropospheric Ozone Chemistry (ARCTOC) campaigns at Ny-Ålesund, Spitsbergen, the role of halogens in the depletion of boundary layer ozone was investigated. In spring 1995 and 1996 up to 30 ppt bromine monoxide were found wheneve
Externí odkaz:
https://doaj.org/article/5b0169696f334a5f9b1f8037a0035891
Autor:
Markus Cornberg, Christoph Sarrazin, Johannes Vermehren, Stefan Zeuzem, Jean-Michel Pawlotsky, Gavin Cloherty, D. Perner, P. Lehmann, Michael P. Manns, Benjamin Maasoumy, Heiner Wedemeyer, Birgit Reinhardt, Birgit Bremer, Katja Deterding, Christoph Höner zu Siederdissen, Martin-Walter Welker
Publikováno v:
Journal of Hepatology. 65:473-482
Background & Aims The European Association for the Study of the Liver (EASL) guidelines recommend HCV RNA measurements at specific time points during sofosbuvir(SOF)-therapy. However, it remains unclear, how these results should be interpreted. We ai
Autor:
Oliver Lenz, Gavin Cloherty, Gaston Picchio, D. Perner, Simone Susser, Bart Fevery, Christoph Sarrazin
Publikováno v:
Antiviral Therapy. 19:559-567
Background Response-guided therapy (RGT) for HCV treatment, whereby therapy duration is shortened according to on-treatment virological response, requires patient HCV RNA concentrations below the lower limit of quantification (LLOQ) or limit of detec
Autor:
Andreas Schober, Georgios Grammatikos, C. Berkowski, B. Hunyadi, Simone Susser, Jörg Petersen, Peter Ferenci, G Felten, Holger Hinrichsen, Thomas Berg, G Knecht, T von Hahn, S Passmann, Beat Müllhaupt, D. Perner, Christoph Sarrazin, Dietrich Hüppe, K.-H. Peiffer, Johannes Vermehren, Peter Buggisch, Maria Buti, Thomas A. Lutz, A. Zipf, Stefan Mauss, Julia Dietz, Stefan Zeuzem
Publikováno v:
Zeitschrift für Gastroenterologie. 54
Autor:
C. Berkowski, S. Zeuzem, Simone Susser, D. Perner, K.-H. Peiffer, Christoph Sarrazin, Johannes Vermehren, N Weiler, M. Raeder, Julia Dietz, S Passmann
Publikováno v:
Zeitschrift für Gastroenterologie. 54
Autor:
Christoph Sarrazin, Stefan Zeuzem, Johannes Vermehren, Simone Susser, D. Perner, Annemarie Berger, Kai-Henrik Peiffer, Regina Allwinn
Publikováno v:
Journal of Clinical Virology. 55:17-22
Virologic response-monitoring is essential for determining therapy duration in patients with chronic hepatitis C virus (HCV) infection. This is usually performed using highly sensitive HCV-RNA assays. However, HCV-RNA assays are time-consuming, expen
Autor:
Simone Susser, Johannes Vermehren, D. Perner, Christoph Sarrazin, C. Füller, Natalia Grigorian, Nicole Forestier, Martin W. Welker, Stefan Zeuzem
Publikováno v:
Journal of Clinical Virology. 52:321-327
a b s t r a c t Background: Telaprevir and boceprevir are highly selective hepatitis C virus (HCV) NS3/4A protea- seinhibitors in phase 3 development. Viral breakthrough during mono- and triple-therapies with PEG-interferon and ribavirin and relapse